Gaucher Disease Therapy (VPRIV) Approved by FDA

Author: U.S. Food and Drug Administration (FDA) - Contact: fda.gov
Published: 2010/02/28 - Updated: 2022/09/20
Contents: Summary - Definition - Introduction - Main - Related

Synopsis: U.S. Food and Drug Administration (FDA) approves velaglucerase alfa for injection (VPRIV) to treat children and adults with a rare genetic disorder, Gaucher disease. VPRIV provides long-term enzyme replacement therapy for Type 1 Gaucher disease, the most common form of the genetic disorder. The safety and effectiveness of VPRIV were assessed in three clinical studies involving 82 patients with Type 1 Gaucher disease ages four years and older. The studies included patients who switched to VPRIV after being treated with Cerezyme.

Introduction

FDA Approves Therapy to Treat Gaucher Disease - New drug will offer a treatment alternative for patients with rare genetic disorder.

Main Digest

Gaucher disease occurs in people who do not produce enough of an enzyme called glucocerebrosidase. Without this enzyme, harmful amounts of a certain fatty substance (lipid) can build up in the liver, spleen, bones, bone marrow, and nervous system and prevent cells and organs from working properly. About 1 in 50,000 to 1 in 100,000 people in the general population have Gaucher disease.

Velaglucerase alfa for injection (VPRIV) provides long-term enzyme replacement therapy for Type 1 Gaucher disease, the most common form of the genetic disorder. It is an alternative to Cerezyme (imiglucerase), another enzyme replacement therapy. Cerezyme is currently in short supply.

"The approval of VPRIV will provide a safe and effective alternative treatment for patients with Gaucher disease," said Julie Beitz, M.D., director of the FDA's Office of Drug Evaluation III. "Patients who previously received Cerezyme as an enzyme replacement therapy for their Type 1 Gaucher disease can be safely switched to VPRIV."

The safety and effectiveness of VPRIV were assessed in three clinical studies involving 82 patients with Type 1 Gaucher disease ages four years and older. The studies included patients who switched to VPRIV after being treated with Cerezyme.

The most common adverse reactions to VPRIV are allergic reactions. Other observed adverse reactions with VPRIV are headache, dizziness, abdominal pain, back pain, joint pain, nausea, fatigue/weakness, fever, and prolonged activated partial thromboplastin time, a measure of clotting time.

VPRIV is manufactured by Shire Human Genetic Therapies Inc. of Cambridge, Mass.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): U.S. Food and Drug Administration (FDA). (2010, February 28 - Last revised: 2022, September 20). Gaucher Disease Therapy (VPRIV) Approved by FDA. Disabled World. Retrieved June 21, 2024 from www.disabled-world.com/medical/pharmaceutical/gaucher-therapy.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/gaucher-therapy.php">Gaucher Disease Therapy (VPRIV) Approved by FDA</a>: U.S. Food and Drug Administration (FDA) approves velaglucerase alfa for injection (VPRIV) to treat children and adults with a rare genetic disorder, Gaucher disease.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.